In turn, any anti‐TGF‐β mAb treatment is unlikely to sufficiently bind and saturate free TGF‐β within the tumor to the extent necessary to reduce tumor growth and invasiveness, consistent with our findings here in animals treated with anti‐TGF‐β only mAb. This evidence concerns the gene TGFB1 and neoplasm.